Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

16 March 2007

Results of liver transplantation for hepatocellular cancer

Krzysztof Zieniewicz, Waldemar Patkowski, Paweł Nyckowski, Abdulsalam Alsharabi, Bogdan Michałowicz, Jacek Pawlak, Rafał Paluszkiewicz, Tadeusz Wróblewski, Bogusław Najnigier, Piotr Smoter, Piotr Hevelke, Anna Skwarek, Piotr Remiszewski, Marcin Kotulski, Michał Skalski, Leszek Pączek, Marek Krawczyk

Ann Transplant 2007; 12(1): 11-14 :: ID: 495357

Abstract

Background: Liver transplantation (LTx) for hepatocellular carcinoma (HCC) in cirrhotic liver is nowadays generally accepted treatment modality.
Aim of Study: Overview of the indications and results of the LTx in the patients with HCC, the first one performed in 2001.
Material/Methods: Among 357 adult liver transplant recipients in the period 1994–04.2005, in 26 (7%) the indication was HCC (16 men: 10 women, age 20–65, mean 46.5 years). HCC developed in cirrhotic liver in 25 pts. 12 (48%) were Child C, 10 (30%) – Child B and 3 (12%) – Child A patients. As underlying disease in 2 patients (8%) was alcoholic cirrhosis, in 7 (28%) – HBV cirrhosis, in 12 (48%) – HCV cirrhosis and in 4 (16%) – HBV/HCV cirrhosis. Milano criteria were met in 20 patients (77%). The mean waiting list time was 2.9 months (range 1–6 months). Seven patients underwent liver resection and 1 transarterial chemoembolization prior to LTx. 11 patients (42%) were operated on with use of veno-venous bypass, in 15 patients (58%) the piggy back technique was applied. Rapamycine based immunosuppression was preferred in post-LTx treatment.
Results: Operative mortality was 0. 4 patients required relaparotomy for intraperitoneal bleeding. 21 patients (81%) are alive in good general condition, 19 – free of the disease. 5 patients died 7–28 months after LTx (mean 16.7). The mean survival time is 20 months (range 1–38).
Conclusions: Liver transplantation is safe and effective method of treatment of the selected patients with HCC in cirrhotic liver. Further investigations concerning the precise indications, timing of the transplantation and adjuvant treatment are necessary.

Keywords: liver transplantation (LTX), Hepatocellular carcinoma (HCC)

Add Comment 0 Comments

In Press

Original article  

Diagnostic Utility of FAR1 Methylation Levels in Hepatocellular Carcinoma Patients Undergoing Liver Transpl...

Ann Transplant In Press; DOI: 10.12659/AOT.951568  

Original article  

Inferior Long-Term Outcome of Fatty Liver Allografts After Orthotopic Liver Transplantation

Ann Transplant In Press; DOI: 10.12659/AOT.950589  

Database Analysis  

Identification and Validation of Liver Transplantation-Induced Acute Lung Injury Biomarkers Using a Bioinfo...

Ann Transplant In Press; DOI: 10.12659/AOT.950289  

Original article  

Survival and Recurrence in Liver Transplant Patients With Intrahepatic Cholangiocarcinoma and Hepatocellula...

Ann Transplant In Press; DOI: 10.12659/AOT.950997  

Most Viewed Current Articles

24 Aug 2021 : Review article   18,372

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

05 Apr 2022 : Original article   14,731

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   14,244

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

29 Dec 2021 : Original article   13,752

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358